# Diabetes Research Hub — Monitor Report
**Run date:** 2026-09-30 (automated Cowork review — no existing files modified)

**Headline:** All pipeline outputs were regenerated overnight (05:28–06:31). Origin is now only **2 commits behind local** (was 126 on 09-29), so the push finally happened. Key new signal: **retatrutide TRIUMPH-2 (T2D+obesity) published in Lancet 2026-09-29** and **petrelintide ZUPREME-1 published in Lancet Diabetes & Endocrinology**; Roche registered a **Phase 3 petrelintide T2D/obesity trial** (NCT07843485).

---

## File System Status

| File | Last modified | Age | Status |
|---|---|---|---|
| `hub_monitor_report.md` | 2026-09-30 05:28 | 0 d | Fresh, but see caveat |
| `clinical_trials_latest.json` | 2026-09-30 06:16 | 0 d | Fresh (907 trials) |
| `pubmed_recent_latest.json` | 2026-09-30 06:31 | 0 d | Fresh (167 papers, 17 domains) |
| `literature_gap_data.json` | 2026-09-30 05:50 | 0 d | Fresh (30 domains, 435 pairs) |
| `literature_gap_report.md` | 2026-09-30 06:23 | 0 d | Fresh |
| `Diabetes_Research_Tracker.xlsx` | 2026-07-17 | **75 d** | STALE |
| `.~lock.Diabetes_Research_Tracker.xlsx#` | 2026-03-15 | 199 d | Stale lock file still present |

**hub_monitor caveat:** the report says 1,460 new / 1,453 removed files. That is a path-format artifact (backslash vs. forward-slash keys between scans), not real churn. Real changes: only `Platform_Audit_Report.docx` and `Research_Findings_Summary.md` modified. The monitor's diff logic should normalize path separators.

**Git:** `main` is ahead of `origin/main` by 2 (was 126). 141 tracked files show as modified/uncommitted (mostly `Analysis/Results` caches and `agent_state.json`). Note: `.git/index.lock` could not be unlinked from this sandbox (harmless for this read-only review).

## Clinical Trial Changes (vs snapshot 2026-09-27; 900 → 907)
**New (8):**
- **NCT07843485** — Roche, **Phase 3**, petrelintide in overweight/obesity + T2D, NOT_YET_RECRUITING, N=600, start 2026-09-30, completion 2029-01. First Phase 3 in the amylin-analogue pipeline for T2D.
- **NCT07845955** — JAK1 inhibitor ivarmacitinib for islet function in T1D, Phase 2, N=132, not yet recruiting (relevant to the baricitinib/JAK track).
- **NCT07843862** — HRS-4729 (Fujian Shengdi), Phase 2, T2D.
- **NCT06534411** — Novo, **Phase 3 COMPLETED**: CagriSema vs tirzepatide in T2D on metformin, N=1,023 (completed 2026-07-09; no results posted yet).
- Four completed-with-results studies (NCT04959487, NCT05860413, NCT06190808, NCT06370715 Lilly LY900014 Phase 4).

**Removed (1):** NCT05757713 (Sanofi, teplizumab pediatric Stage 2) — was ACTIVE_NOT_RECRUITING; verify whether withdrawn/renumbered.
**Status changes (1):** NCT07724340 (Antag Therapeutics, AT673 co-administration) RECRUITING → ACTIVE_NOT_RECRUITING.

**Phase 3 RECRUITING, tracked orgs (9):** Vertex 2 (NCT04786262, NCT06832410 — VX-880), Lilly 4 (baricitinib NCT07222332 & NCT07222137; dulaglutide pediatric NCT06739122; orforglipron NCT07613307), Novo 3 (CagriSema NCT07564414, NCT07282613; zenagamtide AMBITION 7 NCT07797335), Sana 0. Unchanged from 09-27.

**Results posted this month (still awaiting human review):** NCT06045221 (orforglipron vs semaglutide, T2D, N=1,698; posted 09-15) and NCT05872620 (orforglipron, obesity+T2D; posted 09-04). Also NCT05232071 (Inventiva, 09-09). **Evidence level:** registry-posted results only = unreviewed; do not cite until a paper/PMID is verified.

## PubMed Highlights (30-day lookback; 167 papers; 46 new vs 09-29 pull)
**Key-therapy papers (highest priority):**
- **PMID 42810372** — Retatrutide in adults with obesity and T2D (**TRIUMPH-2**), *Lancet*, 2026-09-29. Peer-reviewed RCT; verify PMID and effect sizes before adding to `Research_Findings_Summary.md`.
- **PMID 42810355 / 42810353** — Petrelintide ZUPREME-1 RCT + commentary, *Lancet Diabetes Endocrinol*.
- PMID 42744908 — cagrilintide + retatrutide, *Nature Metabolism*; PMID 42673585 — GLP-1/co-agonist meta-analysis, *Ann Intern Med*.
- PMID 42720752 — beta-cell preservation in new-onset stage 3 T1D, *Diabetologia*.
- 30-day counts: dapagliflozin 50, finerenone 33, orforglipron 12, retatrutide 12, icodec 8, teplizumab 7, efsitora 5, cagrilintide 5, CagriSema 4, amycretin 3, petrelintide 3, baricitinib 2, **zimislecel 0**.

**Cross-domain (multi-domain hits):** 25 papers. Most relevant: PMID 42626948 (gene-edited hypoimmune islets; Stem Cell Cure × Immunotherapy × teplizumab), PMID 42739778 (islet transplant preservation, Stem Cell × Immunotherapy), PMID 42767751 (SIRENA protocol, islet autoimmunity cohort), PMID 42803913 (amylin agonists across 4 domains). Multi-omics/biomarker overlaps: PMID 42803644 (proteomics+metabolomics, cardiometabolic risk), PMID 42799253 (MOFA+), PMID 42808259 (twin epigenetic/HbA1c) — aligned with Tier 1 #1.

**Volume:** Highest: Diabetes AI/ML (207), T2D GLP-1 (203), Microbiome (143), Biomarker (123). Thinnest: Drug Repurpose (3), GLP-1 Pharmacogenomics (3), Epigenetics (7). Zimislecel continues to have zero 30-day hits.

## Gap Analysis Summary (data 0 days old; all BRONZE, single-source)
Top 5 (all gap score 100.0): 1) Beta Cell Regen × Health Equity (0 joint pubs); 2) Insulin Resistance × Islet Transplant (1); 3) Islet Transplant × GWAS/Polygenic (0; flagged in report as methodologically distinct); 4) Islet Transplant × Personalized Nutrition (0; also methodologically distinct); 5) Islet Transplant × Drug Repurposing (0). Report's curated "meaningful" list places Islet Transplant × Drug Repurposing at #3 and also lists Gene Therapy × LADA, Drug Repurposing × Health Equity/LADA.
**Tier 1 alignment:** Drug Repurposing pairs (Islet Transplant, LADA, Health Equity, Glucokinase) map to Tier 1 #4 (Drug Repurposing Computational Screening); Health Equity pairs map to the literature-synthesis track (#2). Gap scores are relative, keyword-based; require expert confirmation (Doctrine).

## Breaking News (web, last ~7 days)
- Retatrutide TRIUMPH-2 in *Lancet* (see above) — peer-reviewed, significant.
- EASD 2026 (Milan) previews list new retatrutide, orforglipron and Novo amylin data (press/preview only = sponsor-reported, Bronze until abstracts/papers are verified). Web search this run returned only headline/URL lists; no additional FDA action beyond those already logged on 09-28/29 (Onswik/efsitora approval, finerenone T1D-CKD) could be confirmed.

Sources: [EASD 2026 preview (Medscape)](https://www.medscape.com/viewarticle/easd-2026-feature-new-diabetes-approaches-2026a1000zk0), [5 Notable FDA Approvals, first half of September (AJMC)](https://www.ajmc.com/view/5-notable-fda-approvals-from-the-first-half-of-september)

## Recommended Actions
1. **Verify and log TRIUMPH-2 (PMID 42810372)** and ZUPREME-1 (PMIDs 42810355/42810353) in `Research_Findings_Summary.md` — check PMIDs/effect sizes against PubMed first.
2. Update `Diabetes_Research_Tracker.xlsx` (75 d stale): add NCT07843485 (Roche petrelintide Ph3), NCT07845955 (ivarmacitinib T1D), NCT06534411 (CagriSema vs tirzepatide, completed); delete the March `.~lock` file.
3. Check why NCT05757713 (teplizumab pediatric Stage 2) dropped from the registry pull.
4. Review orforglipron results NCT06045221 / NCT05872620 once the publication is available.
5. Fix `hub_monitor.py` to normalize path separators (false 1,460 new/1,453 removed).
6. Commit or ignore the 141 modified tracked files (caches, `agent_state.json`); push the remaining 2 commits: `git push origin main`.
7. Watch EASD abstracts; re-run `python baseline_pubmed_alerts.py` next week (gap data is fresh — next refresh not needed before ~2026-10-14).

---
*Generated by automated Cowork review. Sources: Analysis/Results files, git status, web searches.*
